vs
Side-by-side financial comparison of Datavault AI Inc. (DVLT) and REGENXBIO Inc. (RGNX). Click either name above to swap in a different company.
Datavault AI Inc. is the larger business by last-quarter revenue ($33.8M vs $30.3M, roughly 1.1× REGENXBIO Inc.). Datavault AI Inc. runs the higher net margin — 2.0% vs -221.3%, a 223.3% gap on every dollar of revenue. On growth, Datavault AI Inc. posted the faster year-over-year revenue change (3649.6% vs 43.0%). Datavault AI Inc. produced more free cash flow last quarter ($-734.0K vs $-52.8M). Over the past eight quarters, Datavault AI Inc.'s revenue compounded faster (1051.7% CAGR vs 39.4%).
Datavault AI Inc develops AI-powered data management and integration solutions, serving enterprise clients across the United States and North America. Its offerings help organizations unify disparate data assets, streamline analytics workflows, and accelerate machine learning model development and deployment.
REGENXBIO Inc. is a clinical-stage biotechnology firm focused on gene therapy for rare severe genetic diseases. It licenses its proprietary AAV vector technology to global biopharma partners, and advances its own pipeline targeting ophthalmology, metabolic and neurodegenerative disorders.
DVLT vs RGNX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $33.8M | $30.3M |
| Net Profit | $661.0K | $-67.1M |
| Gross Margin | 89.3% | — |
| Operating Margin | 12.3% | -190.0% |
| Net Margin | 2.0% | -221.3% |
| Revenue YoY | 3649.6% | 43.0% |
| Net Profit YoY | 110.4% | -31.2% |
| EPS (diluted) | $0.53 | $-1.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $33.8M | $30.3M | ||
| Q3 25 | $2.9M | $29.7M | ||
| Q2 25 | $1.7M | $21.4M | ||
| Q1 25 | $629.0K | $89.0M | ||
| Q4 24 | $902.0K | $21.2M | ||
| Q3 24 | $1.2M | $24.2M | ||
| Q2 24 | $345.0K | $22.3M | ||
| Q1 24 | $255.0K | $15.6M |
| Q4 25 | $661.0K | $-67.1M | ||
| Q3 25 | $-33.0M | $-61.9M | ||
| Q2 25 | $-37.1M | $-70.9M | ||
| Q1 25 | $-9.6M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $-5.1M | $-59.6M | ||
| Q2 24 | $-42.7M | $-53.0M | ||
| Q1 24 | $2.7M | $-63.3M |
| Q4 25 | 89.3% | — | ||
| Q3 25 | 3.3% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 11.0% | — | ||
| Q4 24 | 24.6% | 70.2% | ||
| Q3 24 | 19.3% | 48.8% | ||
| Q2 24 | 3.2% | 52.5% | ||
| Q1 24 | — | 72.6% |
| Q4 25 | 12.3% | -190.0% | ||
| Q3 25 | -508.1% | -176.3% | ||
| Q2 25 | -718.1% | -296.3% | ||
| Q1 25 | -1499.4% | 13.6% | ||
| Q4 24 | — | -242.1% | ||
| Q3 24 | -447.4% | -256.6% | ||
| Q2 24 | -1566.7% | -251.3% | ||
| Q1 24 | -1630.6% | -408.8% |
| Q4 25 | 2.0% | -221.3% | ||
| Q3 25 | -1135.5% | -208.3% | ||
| Q2 25 | -2139.3% | -331.8% | ||
| Q1 25 | -1520.3% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | -434.5% | -246.3% | ||
| Q2 24 | -12366.7% | -237.7% | ||
| Q1 24 | 1061.6% | -405.4% |
| Q4 25 | $0.53 | $-1.30 | ||
| Q3 25 | $-0.33 | $-1.20 | ||
| Q2 25 | $-0.54 | $-1.38 | ||
| Q1 25 | $-0.18 | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | $-1.39 | $-1.17 | ||
| Q2 24 | $-11.89 | $-1.05 | ||
| Q1 24 | $-5.35 | $-1.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.0M | $230.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $238.0M | $102.7M |
| Total Assets | $274.7M | $453.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $230.1M | ||
| Q3 25 | $1.7M | $274.2M | ||
| Q2 25 | $662.0K | $323.3M | ||
| Q1 25 | $171.0K | $267.9M | ||
| Q4 24 | $3.3M | $234.7M | ||
| Q3 24 | $3.9M | $255.5M | ||
| Q2 24 | $6.1M | $290.4M | ||
| Q1 24 | $2.8M | $338.7M |
| Q4 25 | $238.0M | $102.7M | ||
| Q3 25 | $99.5M | $161.5M | ||
| Q2 25 | $74.1M | $213.7M | ||
| Q1 25 | $81.7M | $274.2M | ||
| Q4 24 | $85.7M | $259.7M | ||
| Q3 24 | $4.3M | $301.4M | ||
| Q2 24 | $6.4M | $348.3M | ||
| Q1 24 | $-2.7M | $390.7M |
| Q4 25 | $274.7M | $453.0M | ||
| Q3 25 | $138.7M | $525.2M | ||
| Q2 25 | $120.7M | $581.0M | ||
| Q1 25 | $95.7M | $490.9M | ||
| Q4 24 | $100.6M | $466.0M | ||
| Q3 24 | $8.0M | $519.1M | ||
| Q2 24 | $10.6M | $569.4M | ||
| Q1 24 | $6.9M | $629.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-406.0K | $-52.3M |
| Free Cash FlowOCF − Capex | $-734.0K | $-52.8M |
| FCF MarginFCF / Revenue | -2.2% | -174.0% |
| Capex IntensityCapex / Revenue | 1.0% | 1.7% |
| Cash ConversionOCF / Net Profit | -0.61× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-126.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-406.0K | $-52.3M | ||
| Q3 25 | $-10.4M | $-56.0M | ||
| Q2 25 | $-6.8M | $-49.3M | ||
| Q1 25 | $-6.0M | $33.6M | ||
| Q4 24 | $-17.5M | $-31.6M | ||
| Q3 24 | $-4.2M | $-40.5M | ||
| Q2 24 | $-5.5M | $-45.5M | ||
| Q1 24 | $-3.5M | $-55.5M |
| Q4 25 | $-734.0K | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | $-6.1M | $32.6M | ||
| Q4 24 | $-17.6M | $-32.7M | ||
| Q3 24 | $-4.2M | $-40.9M | ||
| Q2 24 | $-5.5M | $-46.0M | ||
| Q1 24 | $-3.5M | $-56.0M |
| Q4 25 | -2.2% | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | -966.0% | 36.6% | ||
| Q4 24 | -1946.9% | -154.2% | ||
| Q3 24 | -361.7% | -168.9% | ||
| Q2 24 | -1599.7% | -206.2% | ||
| Q1 24 | -1390.6% | -358.5% |
| Q4 25 | 1.0% | 1.7% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.0% | 1.8% | ||
| Q1 25 | 8.3% | 1.2% | ||
| Q4 24 | 3.9% | 5.1% | ||
| Q3 24 | 0.7% | 1.3% | ||
| Q2 24 | 4.1% | 2.1% | ||
| Q1 24 | 2.4% | 3.6% |
| Q4 25 | -0.61× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.31× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DVLT
| Eos Technology Holdings Inc. | $30.0M | 89% |
| Consumer Audio Products Components And Other Revenue Net | $3.2M | 9% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
